Search

Displaying results 2741 - 2750 of 10000 in total
  1. Target

    Leucine-rich repeat serine/threonine-protein kinase 2

    go.drugbank.com/bio_entities/BE0009457
    TargetHumans

    Serine/threonine-protein kinase which phosphorylates a broad range of proteins involved in multiple processes such as neuronal plasticity, innate immunity, autophagy, and vesicle trafficking (PubMed:17114044, PubMed:20949042, PubMed:2185...

    Polypeptides: Leucine-rich repeat serine/threonine-protein kinase 2
  2. Target

    F-box-like/WD repeat-containing protein TBL1X

    go.drugbank.com/bio_entities/BE0012106
    TargetHumans

    F-box-like protein involved in the recruitment of the ubiquitin/19S proteasome complex to nuclear receptor-regulated transcription units (PubMed:14980219). … Probably acts as integral component of corepressor complexes that mediates the recruitment of the 19S proteasome complex, leading to the subsequent proteasomal degradation of transcription repressor complexes

    Polypeptides: F-box-like/WD repeat-containing protein TBL1X
  3. Drug

    Belantamab mafodotin

    go.drugbank.com/drugs/DB15719
    ApprovedInvestigationalWithdrawn

    [A216756] Belantamab mafodotin was granted FDA accelerated approval on 5 August 2020 for the treatment of multiple myeloma;[L15326] however, its manufacturer began the process for withdrawal of the … In the meantime, belantamab mafodotin will be available for patients in the Risk Evaluation and Mitigation Strategy (REMS) program who can enrol in a compassionate use program.

  4. Drug

    Evinacumab

    go.drugbank.com/drugs/DB15354
    ApprovedInvestigational

    Evinacumab is novel in its mechanism of action compared with other lipid-lowering therapies and therefore provides a unique and synergistic therapeutic option in the treatment of HoFH. … The ANGPTL family of proteins serve a number of physiologic functions - including involvement in the regulation of lipid metabolism - which have made them desirable therapeutic targets in recent years.

  5. Drug

    Dimethicone 410

    go.drugbank.com/drugs/DB14005
    Approved

    [L1769] It is currently recognized by the FDA as a skin protectant OTC ingredient for human use in a concentration of 1-30%. … It is reported that the term dimethicone includes the notation of polydimethylsiloxane and trimethylsiloxy-terminated fluids between 20-30,000 cSt (viscosity).[L2163]

  6. Drug

    Hexocyclium

    go.drugbank.com/drugs/DB06787
    Approved

    Hexocyclium is a muscarinic acetylcholine receptor antagonist which was presumably used in the treatment of gastric ulcer or diarrhea. … Proton pump inhibitors like [DB00338] and opiate anti-diarrheal agents like [DB00836] have largely replaced the use of anti-muscarinics in the treatment of gastric ulcers and diarrhea due to their more

  7. Drug

    Zavegepant

    go.drugbank.com/drugs/DB15688
    ApprovedInvestigational

    of oral zavegepant (150 mg bid) in subjects with mild allergic asthma. … [A258190,A258195] In March 2023, the FDA approved the use of zavegepant nasal spray for the acute treatment of migraine with or without aura in adults.

    Synonyms: 1-piperidinecarboxamide, 4-(1,2-dihydro-2-oxo-3-quinolinyl)-n-((1r)-1-((7-methyl-1h-indazol-5-yl)methyl)-2-(4-(1-methyl-4-piperidinyl)-1-piperazinyl)-2-oxoethyl)-
  8. Drug

    Chlormerodrin Hg-197

    go.drugbank.com/drugs/DB09406
    Approved

    Chlormerodrin Hg-197 is a radiolabelled form of chlormerodrin, an organomercury compound that was previously used as a diuretic. Its radiolabelled form was used as diagnostics in brain scans.

    Synonyms: Chlormerodrin Hg 197, Chlormerodrin Hg-197
  9. Drug

    Abaloparatide

    go.drugbank.com/drugs/DB05084
    ApprovedInvestigational

    [L740] It was first approved by the FDA on April 28, 2017,[A256748] for the treatment of osteoporosis in postmenopausal women and is also used to increase bone density in men with osteoporosis. … [L740] In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended abaloparatide be granted marketing authorization in Europe [L43552] and the drug was fully authorized

  10. Drug

    Chromic chloride

    go.drugbank.com/drugs/DB09129
    Approved

    Chromic chloride, for injection, is a sterile, nonpyrogenic solution intended for use as an additive to solutions for Total Parenteral Nutrition (TPN).

    Mixtures: ADDAMEL N 20 AMPUL, M T E 4 Concentrate InjCategories: Compounds used in a research, industrial, or household setting